Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Institut de Recherches Internationales Servier (France)
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Registry to provide contemporary information regarding characteristics, management and outcomes of outpatients with stable coronary artery disease
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Phase I study of S 78454 in combination with a fixed dose infusion of cisplatin in patients with advanced solid tumours
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily in patients with chronic stable angina pectoris
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Evaluation of efficacy and clinical benefit of agomelatine in patients with major depressive disorder compared to serotonin-norepinephrine reuptake inhibitor (SNRI)
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Long-term effects of strontium ranelate on knee osteoarthritis symptoms: a two year prospective, randomised, placebo-controlled study
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
A study to determine the maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder. A 8 to 10 weeks open period treatment with agomelatine followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period
Not provided at time of registration and not expected to be available in the future
Country
Australia
,
Finland
,
France
,
South Africa
,
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Efficacy and safety of agomelatine given orally compared to placebo, in addition to a mood stabiliser in bipolar I patients with a current major depressive episode. An eight week randomised, double-blind, controlled, parallel group study followed by a double-blind extension treatment period up to one year
Not provided at time of registration and not expected to be available in the future
Country
France
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Effect of agomelatine on cerebral activity measured by functional magnetic resonance imaging (MRI) in patients with major depressive disorder in comparison to healthy volunteers
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Phase I dose-escalation study of S 49076 in patients with advanced solid tumours
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Institut de Recherches Internationales Servier (France)
Update Il y a 4 ans
Effect of trimetazidine MR 35 mg on the emergence of choroidal neovascularisation in age-related macular degeneration
Not provided at time of registration and not expected to be available in the future
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
Next